Biotech

Therma Bright Inc (TSXV:THRM) (OTCQB:TBRIF) Signs The Exclusive Worldwide Licensing Rights To Market And Sell Ai4lyf’s Digital Cough Technology (Dct)

Feb 16, 2023

The medical devices industry has grown at a decent clip over the course of the past years and one of the companies which could be worth looking into at this point is Therma Bright Inc (TSXV:THRM) (OTCQB:TBRIF). The company is currently best known for having developed the smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test but it has been working on other devices as well.

This morning the company has come into the news cycle after it announced that it had inked the exclusive global licensing rights to sell and market AI4LYF’s Digital Cough Technology (DCT). It was another major development for the company and one that is expected to bring Therma Bright onto the radars of investors.

The most important thing to point out with regard to DCT is the fact that the technology can help in detecting a range of respiratory diseases instantly and that includes COVID-19. The technology is deployed through a smartphone application and it can work anywhere at any time.

More importantly, the exclusive license is particularly important for Therma Bright. That would allow the company to work on the development of DCT solutions for detecting other diseases like bronchiolitis, asthma, and pneumonia among others.

It goes without saying that the latest development could well be a significant one for Therma Bright and investors could consider keeping an eye on the stock. Back in November 2022, it had been announced that the patent-pending DCT solutions was a revolutionary technology, powered by an artificial intelligence engine, which could change the way respiratory diseases were detected.

For instance, the app can come up with a result for the COVID-19 test within a minute and more importantly, it has managed to clock an accuracy rate of as much as 94%.

Small Cap Exclusive is owned and operated by King Tide Media, which is a US based corporation has been compensated $60,000 from Therma Bright Inc for profiling TBRIF for 30 days starting Feb 21 2023. We own ZERO shares in TBRIF.

FSD Pharma Inc. (HUGE) Is Bullish On ALL 19 Technical Indicators

Feb 8, 2023

FSD Pharma Inc. HUGE stock could be heading to the moon, look at this chart below!

Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:

#1 All Technical Indicators & The Chart Are BULLISH

#2 Canada Greenlighted Phase 1 Trial for Multiple Sclerosis

#3 The Stock Has A History Of Big MOVES

FSD Pharma Growing Systems Company Summary

Company Name: FSD Pharma Inc.

Ticker: HUGE

Exchange: NASDAQ

Website: https://fsdpharma.com/

Company Summary: FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

No need to really discuss this in great detail, this is incredibly rare to have all 19 technical indicators on Yahoo and Market Watch agreeing that this stock is BULLISH.

There are no Guarantees in the stock market BUT this is as close as we have ever seen!

Seeking Alpha wrote an amazing article on FSD Pharma Inc. (NASDAQ:HUGE) and we include an excerpt from it below.

“The shares of Canadian biotech FSD Pharma (NASDAQ:HUGE) rose for the fourth consecutive session on Tuesday after announcing that Canada greenlighted its Phase 1 trial for multiple sclerosis candidate LUCID-21-302.

Issuing a No Objection Letter (NOL), Health Canada has granted the regulatory nod to start the first-in-human clinical trial for LUCID-21-302 in the country, FSD (HUGE) said without detailing the estimated timeline for the study.

“We will continue to work with Health Canada and other regulators worldwide to complete clinical investigations as soon as we can,” Chief Executive Lakshmi Kotra remarked.

Preclinical studies have indicated the potential of LUCID-21-302 in the prevention of myelin degradation, which is believed to result in neurogenerative diseases such as MS, where there is damage to the myelin sheath in neuronal cells.

The Toronto-based pharma announced in September that the US and Canadian regulators cleared its mid-stage trial for FSD201 to treat a form of pain caused by the abnormal functioning of the body’s mast cells called idiopathic mast cell activation (IMCA) syndrome.“

Press Release Below

February 7th 2023

TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announces the receipt of a No Objection Letter (“NOL”) from Health Canada regarding the Company’s proposed Phase 1 clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of Multiple Sclerosis (“MS”). The NOL provides FSD Pharma with regulatory approval to move forward with the clinical trial in Canada.

Look at this BEAST, exploding from $1.36 to $4.09 representing 200% gains!

WOW, $17 to $154 representing almost 1,000% gains. Furthermore, the fact that it was at $154 pre-covid and supply chain difficulties reveals the MASSIVE potential of this burgeoning Wall Street darling!

Let’s recap!

Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:

#1 All Technical Indicators & The Chart Are BULLISH

#2 Canada Greenlighted Phase 1 Trial for Multiple Sclerosis

#3 The Stock Has A History Of Big MOVES

Happy Trading!

DISCLAIMER

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has not been compensated for profiling HUGE. We own ZERO shares in HUGE.

FULL DISCLAIMER

TCBP Stock: TC BioPharm (NASDAQ:TCBP) Stock On Radar Ahead of A Key Event

Jan 31, 2023

Clinical-stage biotech company TC BioPharm (NASDAQ:TCBP) has seen it’s stock considerable momentum over the course of the past month and it could well be a good time to start taking a deeper look into it. In the past week, TCBP stock clocked gains of 13% and that took the gains made by it over the course of the past month to as much as 40%.

The company is mainly involved in the development of platform allogeneic gamma-delta T cell therapies which are meant for treating cancer.

TC BioPharm

Company Name: TC BioPharm

Ticker: TCBP

Exchange: NASDAQ

Website: https://www.tcbiopharm.com/

Adamas One Corp Summary:

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

Here are the latest news from TCBP stock:-

#1 All Eyes On Shareholder Update Call

The company was in the news last week on January 20 when it announced that it was going to come up with a shareholder update on February 20, 2023, at 10 in the morning Eastern Standard Time.

In that particular update, the management of TC BioPharm would be looking to provide a detailed update with regard to the trial plan for the allogeneic gamma delta therapeutic in different oncology indications. There will also be a question and answer session after CFO Martin Thorp and CEO Bryan Kobel complete their remarks.

It would be interesting to see how would TCBP stock react after the event.

#2 Receives Notice of Non-compliance with NASDAQ’s Listing Rule 5550(b)(1)

On January 19, it emerged that TC BioPharm had been provided with a written notification from NASDAQ with regards to the fact that it had failed to regain compliance as per the minimum Market Value of Listed Securities threshold of $35,000,000. That figure is the minimum for continued listing on the exchange.

The company announced at the time that it was going to present the exchange with a comprehensive plan on how it was going to address the situation and regain compliance.

#3 Strategic Collaboration to Advance Gamma Delta T Cells in Oncology

Another major development with regards to TC BioPharm was the announcement from the company earlier this month on January 17 that it had decided to get into collaboration with the celebrated University of Texas MD Anderson Cancer Center.

The collaboration would be focussed on expanding the knowledge with regard to the deployment of gamma-delta T cells in oncology. It remains to be seen if TCBP stock can hold onto its momentum this week.

So, keep an eye on TCBP stock as shareholders would reach to the company’s upcoming earnings and we may see high volatility. Get more lists of stocks here

NMRD Stock: Why is Nemaura Medical (NASDAQ: NMRD) A Top Stock To Watch in February?

Jan 26, 2023

Over the past week, the Nemaura Medical Inc (NASDAQ: NMRD) stock has been in the middle of a solid rally and recorded gains of 56% to emerging as one of the stock to watch. As it happens, the NMRD stock hit its highest level since mid-October last year.

Nemaura Medical Inc

Company Name: Nemaura Medical Inc

Ticker: NMRD

Exchange: NASDAQ

Website: https://nemauramedical.com

Nemaura Medical Inc Summary:

Nemaura Medical Inc. is a medical technology company developing and commercialising non-invasive wearable diagnostic devices. The Company is currently also commercialising sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, as a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes.

There are certain specific triggers that led to the remarkable rally in the NMRD stock.

#1 Medical’s Program Shows Weight Loss In 100% Of Participants

One of those came about earlier in the week on January 24 when the company announced the initial results from the patient studies that had been conducted with the National Health Service (NHS) of the United Kingdom for Miboko, its metabolic health program.

The results were positive as the patients recorded an average weight loss of 3.7 pounds and all the patients experienced some degree of weight improvement.

This news had a major positive impact on NMRD stock and is one of the top stock to watch.

#2 Commences Pilot Program of Miboko with the NHS

While that was quite clearly a significant development it should be noted that the announcement with regards to the study for Miboko in collaboration with the NHS had been announced back on November 29, 2022.

Mikobo is the first product in its category to have a non-invasive glucose sensor in a lifestyle app. It not includes information with regard to drinking and good intake but also provides analytics and educational content. At the end of the analysis, the app provides the user with a metabolic score based on diet and other important factors.

#3 Solid Industry Growth

Nemaura is entering the Continuous Glucose Monitoring Market with the product and it is a market that is expanding rapidly. The market was worth as much as $6.13 billion back in 2021 and by 2030 it is expected to command a valuation of $16.33 billion, which reflects a CAGR of 17.33%.

So, considering the latest news and big jump, NMRD stock is one of the other top stock to watch for the month of February.

Avalon GloboCare’s (Nasdaq: ALBT) Fusion Gene Map Technology Could Be The Greatest Investment?

Jan 9, 2023

Literally, this could be the best investment of the year.

Why, think about this!

Avalon is establishing a leading role in the fields of cellular immunotherapy, exosome technology (ACTEX™), and regenerative therapeutics.

Why is that a big deal?

The global cellular immunotherapy size is expected to reach USD 37.97 billion by 2030!

It is estimated to register a CAGR of 22.41% during the forecast period.

This amazing growth is driven by the growing government support for innovative therapies research, rising prevalence of cancer & development of advanced cell-based immunotherapies.

Now before we get into the top 4 reasons we like ALBT, let’s do a quick summary on the company.

Avalon GloboCare Company Summary

Company Name: Avalon GloboCare Corp.

Ticker: ALBT

Exchange: NASDAQ

Website: www.avalon-globocare.com

Avalon GloboCare Company Summary:

Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.

Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.

💥 RECESSION PROOF 💥

Historically, what is a great market segment to invest in during a recession, Medical!

In my opinion, The hottest vertical within The Medical market is biotech stocks.

They are safe and recession-proof.

After all, we can’t stop people from aging or from seeking treatments for a myriad of issues.

Plus, there’s growing demand for innovation in gene therapies, immune-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs.

According to Grand View Research, the global biotech industry could be worth up to $2.44 trillion by 2028.

The global cellular immunotherapy market size is expected to reach

USD 37.97 billion by 2030!

It is estimated to register a CAGR of 22.41% during the forecast period.

In THREE trading days this stock went up 40%!

Also, it created a base at $4 before it ran 40%!

GUESS WHAT?! It is at $4 again and appears to be ready to run!

Take a look at the buy ratings in #4 Section from Investing.com, Stock.ta and American Bulls!

3 TRUSTED sources saying, “BUY”

Now, let’s look mat what is driving these ratings and explosive gains, the amazing press released by ALBT below.

Jan. 03, 2023

Announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.

In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal. Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.

Dec. 14, 2022

Announced that the Company completed a private placement of shares of its Series A preferred stock with the Company’s Chairman, Daniel Lu. The gross proceeds of the offering were $4.0 million, which is in addition to the previously announced private placement of $5 million of Series A preferred stock, all of which will be used to pay a portion of the purchase price for the announced acquisition of Laboratory Services MSO, LLC.

As previously announced, the Company’s Series A preferred stock is convertible into shares of the Company’s common stock at price per share equal to the greater of $1.00 or 90% of the closing price of the Company’s common stock on the Nasdaq Stock Market on the day prior to conversion. All holders of the Series A preferred stock will be restricted from selling the shares of common stock issuable upon conversion of the Series A preferred stock for a period of 9 months and will be limited to selling no more than 10% of their shares of common stock in any calendar month.

Sept. 29, 2022

The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.

ALBT has a 52-week high of $9.40, which is MORE THAN DOUBLE compared to current levels. In fact, it would be upside of 126% if the stock climbs back there.

ALBT even has a STRONG BUY Rating From Highly Respected Investing.com!

ALBT also has a BULLISH sentiment from StockTa.com right now which can be seen HERE.

Additionally, the stock has a STAY LONG rating at AmericanBulls.com which can be seen below:

Currently ALBT boasts a relatively small trading float for a NASDAQ stock at a little over $13M.

Wall Street is still uncovering this hidden gem and with a small number of shares available for trading, a sudden demand could create a major sudden upswing in price.

Now let’s review the 4 reasons we encourage you to turn your attention to ALBT.

As a quick reminder of the 4 REASONS why you should pull up ALBT right now:

BioTech Market Is Recession Proof

The Chart Looks Like an “Ideal Setup”

The Press Releases are Simply Incredible

Buy Rating Issued from Investing.com

Source 1: https://www.grandviewresearch.com/press-release/global-cellular-immunotherapy-market

Source 2: https://www.grandviewresearch.com/industry-analysis/cellular-immunotherapy-market-

FULL DISCLAIMER

Omega Therapeutics OMGA Stock Price is ready to take off? URGENT

Jul 6, 2022

Omega Therapeutics OMGA Stock Price has been trying to recover since it’s November high of almost $30.

Wondering why this stock is having such a hard time and if it can break the overall trend? Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!

<!-- TradingView Widget BEGIN -->
<div class="tradingview-widget-container">
  <div class="tradingview-widget-container__widget"></div>
  <div class="tradingview-widget-copyright"><a href="https://www.tradingview.com/symbols/AAPL/" rel="noopener" target="_blank"><span class="blue-text">Apple</span></a> by TradingView</div>
  <script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-symbol-overview.js" async>
  {
  "symbols": [
    [
      "Apple",
      "AAPL|1D"
    ],
    [
      "Google",
      "GOOGL|1D"
    ],
    [
      "Microsoft",
      "MSFT|1D"
    ]
  ],
  "chartOnly": false,
  "width": 1000,
  "height": 500,
  "locale": "en",
  "colorTheme": "dark",
  "autosize": false,
  "showVolume": false,
  "showMA": false,
  "hideDateRanges": false,
  "hideMarketStatus": false,
  "hideSymbolLogo": false,
  "scalePosition": "right",
  "scaleMode": "Normal",
  "fontFamily": "-apple-system, BlinkMacSystemFont, Trebuchet MS, Roboto, Ubuntu, sans-serif",
  "fontSize": "10",
  "noTimeScale": false,
  "valuesTracking": "1",
  "changeMode": "price-and-percent",
  "chartType": "line"
}
  </script>
</div>
<!-- TradingView Widget END -->

[thrive_leads id=’14274′]

Before we get started, I wanted to introduce myself to you. Hi 🙋‍♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.

I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.

What do I mean by big winners?

Stocks that move more than 100% in a month! OMGA Stock Price could?

Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!

The article is HERE where I shine a spotlight on trending stocks and breakout stocks!

Now, let’s go over some of the basic information on this stock before we get in the technical analysis

Omega Therapeutics Company Information

Company Name: Omega Therapeutics Inc.

Ticker: OMGA

Exchange: NASDAQ

Website: https://omegatherapeutics.com/

Netlist Inc. Company Summary:

Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.

OMGA stock price is due to News?

June 30, 2022 /

Announced the presentation of new preclinical data on its lead product candidate, OTX-2002, to regulate expression of the c-Myc (MYC) oncogene through epigenetic modulation in multiple models of hepatocellular carcinoma (HCC) in a poster presentation at the European Society of Medical Oncology (ESMO) 2022 World Congress on Gastrointestinal (GI) Cancer, taking place in Barcelona, Spain, June 29 – July 2, 2022.

OMGA 5 Day Chart

OMGA Stock Price Technical Analysis:

I like it over $5 but the 1 day, 5 day and 10 day chart looks great! The news is wonderfule and volume is up!

I like the stock

[thrive_leads id=’14274′]

Humanigen HGEN Stock Price is consolidated and ready for a run? URGENT

Jul 6, 2022

Humanigen HGEN Stock Price has been trying to recover since it’s August high of almost $17.83.

[thrive_leads id=’14274′]

Before we get started, I wanted to introduce myself to you. Hi 🙋‍♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.

I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.

What do I mean by big winners?

Stocks that move more than 100% in a month! HGEN Stock Price could?

Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!

The article is HERE where I shine a spotlight on trending stocks and breakout stocks!

Now, let’s go over some of the basic information on this stock before we get in the technical analysis

Humanigen Inc. Company Information

Company Name: Humanigen Inc.

Ticker: HGEN

Exchange: NASDAQ

Website: https://www.humanigen.com/

Humanigen Inc. Company Summary:

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

HGEN stock price is due to News?

July 6th

announced a peer-reviewed publication in Thorax, one of the world’s leading respiratory medicine journals and the official journal of the British Thoracic Society, describing the role of CRP in identifying patients that derive the greatest benefit of lenzilumab. Participants in the LIVE-AIR study with baseline CRP <150 mg/L treated with lenzilumab demonstrated a 62% reduction in the relative risk of invasive mechanical ventilation and death compared to placebo.¹

HGEN 5 Day Chart

HGEN Stock Price Technical Analysis:

I like it at $2.40 but not below. It is looking really bad on the 1 month and above charts.

Volume is higher than normal and the technical indicators look good for short term plays.

[thrive_leads id=’14274′]

Trevi Therapeutics TRVI Stock Price I called it once, can I again? URGENT UPDATE

Jun 29, 2022

WOW I nailed this, TRVI Stock price shot up after I said, “It looks very good to me!” and… BOOM up 17% in the last 5 days.

Take a look at my technical analysis below from March 2nd, here is the full article.

Trevi Therapeutics TRVI stock price is up 17% in the last 5 days, but can it go higher?

There is an old adage, “two heads are better than one”, so let’s put both our heads together and compare notes on TRVI.

In this in depth report, I look at 5 KPIs: Technical Analysis, Volume, News Cycle, Fundamentals & awareness campaigns. I believe the stock market is not gambling, it is also not fool proof, but I have developed a dependable system. I have found some critical components to success for TRVI, tell me what you think.

Before we get started, I like being methodical and easy to understand so I have developed a ranking system for my stocks. I call it, Alexander Goldman’s “HOT Stock Ranking!”

The official heat level for TRVI is, a 🔥🔥🔥 3 out of 4

Before I get ahead of myself and just jump right into this exciting breakout stock, I wanted to introduce myself.

Hello 🙋‍♂️ My name is Alexander Goldman. I have been trading small cap stocks, breakout stocks and trending stocks for 20 years now. I’m accredited for establishing the coveted HOT Stock Reporting system for breakout stocks.

To find out more about my story, CLICK HERE

[thrive_leads id=’28419′]

Xebec Adsorption Company Information

Company Name: Trevi Therapeutics Inc.

Ticker: TRVI

Exchange: NASDAQ

Website: https://www.trevitherapeutics.com/

Xebec Adsorption Inc Uranium Company Summary:

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

TRVI stock price is due to News?

TRVI Stock Price HOT Stock Grade:

The official heat level for TRVI is, a 🔥🔥🔥 3 out of 4 . Here are my takeaways on it and why it is just a 3 out of 4. Do you agree?

TRVI Trading Volume

The volume, is trading at an increase of 6,818% over the average which indicates a higher demand in the stock.

Trading 101: volume is measured in the number of shares traded. Traders look to volume to determine liquidity and combine changes in volume with technical indicators to make trading decisions. So, let’s take a look at the technical indicators.

TRVI Technicals

The technical analysis “chart reading”, it is a solid move it just made but right now I would wait till it consolidates and beats $2.50.

Trading 101: Technical indicators are technical tools that help in analyzing the movement in the stock prices whether the ongoing trend is going to continue or reverse. It helps the traders to make entry and exit decisions of a particular stock. Technical indicators can be leading or lagging indicators.

TRVI News Cycle

The news, there is significant news, “Increases in revenue” circulating around TRVI stock price. This is a factor in driving the demand, share volume spikes.

TRVI Fundamentals

The fundamentals, there is exciting financial filings associated with this stock, “increases in rev” but based on other key indicators it reduces the overall importance of the revenue due to cash flow issues.

Trading 101: Fundamental trading is a method where a trader focuses on company-specific events to determine which stock to buy and when to buy it. Trading on fundamentals is more closely associated with a buy-and-hold strategy rather than short-term trading.

TRVI Awareness

Marketing efforts “Awareness Campaigns”, I have not found marketing efforts around the investor awareness of this company. Hence the 3 out of 4. Do you agree? Write me a line at [email protected]

Again, two heads are better than one, let’s work together to have the best trading year of our lives!

To receive my 🔥🔥🔥🔥 HOT stock as a thank you for joining our FREE newsletter, sign up today.

To find out more about my story, CLICK HERE

👇 Sign up for our newsletter to get the latest 🔥🔥🔥🔥 HOT stocks and we can compare notes!👇

[thrive_leads id=’28419′]

BTTX Stock Price is up 23%, can it go higher? URGENT

Jun 24, 2022

Better Therapeutics BTTX stock price is up 23% in the last 5 days & volume is down 89% (WOW), but is it over for this breakout stock?

How is it that volume is down so much but it is up 23%?

There is an old adage, “two heads are better than one”, so let’s collaborate on BTTX and compare notes.

Before we get started, I like being methodical and easy to understand so I have developed a ranking system for my stocks. I call it, Alexander Goldman’s “HOT Stock Ranking!”

The official heat level for BTTX is, a 🔥🔥2 out of 4

Before I get ahead of myself and just jump right into this exciting breakout stock, I wanted to introduce myself.

To find out more about my story, CLICK HERE

[thrive_leads id=’28419′]

Better Therapeutics Company Information

Company Name: Better Therapeutics Inc.

Ticker: BTTX

Exchange: NASDAQ

Website: https://www.bettertx.com/

Better Therapeutics Company Summary:

Better Therapeutics, Inc. develops software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. It engages in developing a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.

BTTX stock price is due to News?

June 8th

Announced that the U.S. Patent and Trade Office (USPTO) has granted their first patent, granting twenty years of exclusivity for a number of key features core to the company’s digital therapeutics platform, designed to help treat cardiometabolic diseases through the delivery of digital behavioral therapy as a PDT.

BTTX Stock Price HOT Stock Grade:

The official heat level for BTTX is, a 🔥🔥2 out of 4 . Here are my takeaways on it and why it is just a 3 out of 4. Do you agree?

BTTX Trading Volume

The volume, is trading at an increase of 23% over the average which indicates a higher demand in the stock.

BTTX Technicals

The technical analysis “chart reading”, it is bullish and I like it. The one day, 5 day and ten day chart looks great. Keep this on your watchlist.

BTTX News Cycle

The news, there is no significant news.

BTTX Fundamentals

The fundamentals, there is no exciting financial filings associated with this stock,.

BTTX Awareness

Marketing efforts “Awareness Campaigns”, I have not found marketing efforts around the investor awareness of this company. Hence the 2 out of 4. Do you agree? Write me a line at [email protected]

Again, two heads are better than one, let’s work together to have the best trading year of our lives!

To receive my 🔥🔥🔥🔥 HOT stock as a thank you for joining our FREE newsletter, sign up today.

To find out more about my story, CLICK HERE

👇 Sign up for our newsletter to get the latest 🔥🔥🔥🔥 HOT stocks and we can compare notes!👇

[thrive_leads id=’28419′]

« Older Entries

Next Entries »

Biotech

Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:

Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:

Avalon GloboCare Company Summary

Avalon GloboCare Company Summary:

💥 RECESSION PROOF 💥

3 TRUSTED sources saying, “BUY”

Omega Therapeutics Company Information

Netlist Inc. Company Summary:

OMGA stock price is due to News?

OMGA 5 Day Chart

Humanigen Inc. Company Information

Humanigen Inc. Company Summary:

HGEN stock price is due to News?

HGEN 5 Day Chart

The official heat level for TRVI is, a 🔥🔥🔥 3 out of 4

Xebec Adsorption Company Information

Xebec Adsorption Inc Uranium Company Summary:

TRVI stock price is due to News?

Trending Stock TRVI 5 Day Chart

TRVI Trading Volume

TRVI Technicals

TRVI News Cycle

TRVI Fundamentals

TRVI Awareness

The official heat level for BTTX is, a 🔥🔥2 out of 4

Better Therapeutics Company Information

Better Therapeutics Company Summary:

BTTX stock price is due to News?

Trending Stock BTTX 5 Day Chart

BTTX Trading Volume

BTTX Technicals

BTTX News Cycle

BTTX Fundamentals

BTTX Awareness

We Are Small Cap Exclusive

Email

Phone

Navigation

Quick Links